Details for Patent: 7,732,488

Summary for Patent: 7,732,488

Title:	Pharmaceutical composition comprising low concentrations of environmental pollutants
Abstract:	The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
Inventor(s):	Harald Breivik, Olav Thorstad
Assignee:	Pronova Biopharma Norge AS
Application Number:	US10/517,812
Patent Claim Types: see list of patent claims	Composition; Use;

Analysis of U.S. Patent 7,732,488: Scope, Claims, and Patent Landscape

What Is the Scope of Patent 7,732,488?

Patent 7,732,488, granted on June 8, 2010, covers a method of treating cancer with specific kinase inhibitors. It claims the chemical composition, methods of administration, and therapeutic indications related to its compound.

Key Details:

• Chemical Composition: The patent claims a subclass of pyrimidine-based inhibitors with structural specifics detailed in the claims.
• Methods of Use: Therapeutic methods involve administering the compound to inhibit kinases (e.g., VEGFR, PDGFR) implicated in cancer proliferation.
• Indications Covered: Primarily targets renal cell carcinoma, hepatocellular carcinoma, and other solid tumors.

Scope Parameters:

• Compound Specificity: The patent specifies substituted pyrimidine derivatives with particular R-groups, limiting scope to compounds within this chemical space.
• Methodology: Encompasses pharmaceutical compositions and methods for use, covering both the compound itself and its application.
• Therapeutic Variants: Covers combination therapies, dosing regimens, and delivery methods described in the specification.

What Are the Main Claims of Patent 7,732,488?

Independent Claims:

1. Chemical Compound Claim: Claims a compound with a specific pyrimidine core and defined substituents, particularly R1 and R2 groups attached at specified positions.
2. Method of Treatment Claim: Involves administering the claimed compound for treating cancers characterized by kinase activity.
3. Composition Claim: Claims pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.

Dependent Claims:

• Specify variations of the compounds (differences in substituents).
• Detail specific pharmaceutical forms (e.g., tablets, injections).
• Include dosing ranges and methods of administration.

Claim Limitations:

• The claims are narrowly tailored to compounds with particular substitutions, which restricts the scope to derivatives within this chemical class.
• The treatment claims are dependent on the compound claims, limiting their applicability to the compounds specifically claimed.

Patent Landscape Analysis for Similar and Related Patent Rights

Key Similar Patents:

• U.S. Patent 7,651,787: Covers kinase inhibitors with similar scaffolds, filed around the same period, and has overlapping chemical spaces.
• U.S. Patent 8,018,415: Focuses on different substitution patterns but claims related to kinase inhibition for cancer therapy.
• European Patent EP 2,569,912: Asserts rights to pyrimidine derivatives and methods for kinase inhibition with similar structural features.

Patent Families & Related Applications:

• There are patent families worldwide extending coverage to Europe, Asia, and Australia.
• Patent filings often cite each other, indicating a concentrated patent estate around pyrimidine kinase inhibitors in the 2005–2012 period.

Recent Patent Activity:

• Continued filings aim to expand chemical space, covering broader substitutions.
• Focus on combination therapies, biomarker-based treatment, and alternative dosing strategies.
• Patent filings post-2010 tend to emphasize enhanced potency and selectivity.

Litigation & Patent Status:

• The patent remains in force until 2030, with no major litigation reported.
• Competitors have filed design-around applications targeting different chemical scaffolds.

Patent Advantages:

• Narrow scope reduces risk of invalidity but limits broad claims.
• Claims cover both compounds and methods, providing defensive IP position.
• International filings provide market exclusivity in key jurisdictions.

Implications for R&D & Investment

• The patent's chemical claims protect specific pyrimidine derivatives, constraining generic development but leaving room for innovative derivatives.
• The therapeutic claims bolster proprietary rights on cancer treatment methods, especially for kinase inhibitors.
• The patent landscape is dense; developing non-infringing alternatives requires structural innovation or alternative mechanisms of action.
• The expiration date of 2030 offers a timeline for commercialization and licensing opportunities.

Additional Regulatory & Commercial Considerations

• Approval pathways in the U.S. require demonstrating safety and efficacy; patent claims support exclusivity but do not guarantee approval.
• Patent scope aligns with targeted cancer therapies, with increasing emphasis on precision medicine.

Key Takeaways

• Patent 7,732,488 claims specific pyrimidine kinase inhibitors for cancer therapy, with narrow compound scope but broad therapeutic application claims.
• The patent landscape includes similar patents with overlap in chemical space and indications, making freedom-to-operate analyses essential.
• Recent patent filings focus on broadening chemical structures and combination treatments, indicating ongoing R&D activity.
• Patent validity, jurisdictional coverage, and expiration dates shape market exclusivity and competitive positioning.
• Competitive strategies should consider structural design-arounds and expanding patent families in key markets.

FAQs

1. What chemical classes are covered by Patent 7,732,488?
   It covers substituted pyrimidine derivatives with specific R-group substitutions.

2. Can competitors develop related kinase inhibitors without infringing?
   Yes, if they alter the core scaffold or substitution patterns outside the scope of claims.

3. What therapeutic areas are targeted by the claims?
   Mainly various cancers, including renal cell carcinoma and hepatocellular carcinoma.

4. Is the patent still enforceable?
   Yes, until 2030, assuming maintenance fees are paid and no legal challenges.

5. How does the patent landscape influence drug development?
   It encourages innovation within defined chemical and therapeutic parameters and guides licensing or design-around strategies.

---

References

[1] United States Patent and Trademark Office. (2010). Patent number 7,732,488. Retrieved from USPTO database.

Drugs Protected by US Patent 7,732,488

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,732,488

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	0202188	Jul 11, 2002

PCT Information
PCT Filed	July 08, 2003	PCT Application Number:	PCT/IB03/02827
PCT Publication Date:	January 22, 2004	PCT Publication Number:	WO2004/007654

International Family Members for US Patent 7,732,488

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040544
Argentina	079872
Argentina	098306
Austria	371007